#Canada #Aurora Cannabis #Edmonton #Curaleaf #hostile bid

Aurora Cannabis Issues Critical Update on Curaleaf's Hostile Bid

In a recent statement, Aurora Cannabis Inc. has urged its shareholders to refrain from taking any action regarding Curaleaf Holdings, Inc.'s revised hostile takeover bid. This advisory comes as Aurora's Special Committee embarks on a detailed and independent evaluation of the bid, which has been described as merely an initial step in the deliberation process.

Background of the Hostile Bid

Aurora, a leading global medical cannabis company headquartered in Canada, is currently facing a hostile bid from Curaleaf, a competitor in the cannabis sector. Curaleaf has amended its offer, proposing an implied consideration of US$5.00 per share, which includes both subordinate voting shares of Curaleaf and a cash component for each share of Aurora.

This significant bid has attracted the attention of both companies and investors alike. Aurora's Board of Directors emphasizes that shareholders deserve ample time to analyze the revised proposal, ensuring they can make informed decisions. According to Aurora's leadership team, especially Miguel Martin, the company's Executive Chairman and CEO, the revised bid should not be seen as a prompt for immediate action. Instead, it is part of a broader framework that necessitates a careful review.

The Review Process

The Special Committee has been tasked with scrutinizing the particulars of Curaleaf's offer alongside its financial advisors. This review is expected to inform the Board’s formal recommendation to shareholders, which is anticipated to be issued once the examination is complete. Aurora has assured its shareholders that they will be kept informed throughout this process.

The advisory states that Aurora’s shareholders have until at least December 4, 2026, to ponder their options in light of the bid. Stakeholders are encouraged to remain calm and wait for the Board’s forthcoming communication, which may provide additional context and insights into the bid and its implications for the company’s future.

Shareholder Support and Communication

For shareholders who may have inquiries regarding the hostile bid or wish to stay updated, Aurora has established a direct line of communication via Kingsdale Advisors. This strategic advisor serves as an information resource and is available for direct contact through various means, ensuring shareholders have access to timely information and support.

Interested parties can reach Kingsdale Advisors toll-free throughout North America or via direct calls and texts, as well as through their email. This initiative emphasizes Aurora’s commitment to keeping its investors well-informed and engaged during this crucial period.

About Aurora Cannabis

Aurora Cannabis is recognized as a frontrunner in the medical cannabis industry, with a dedication to enhancing lives through scientific expertise and a solid focus on patient care. Their portfolio includes trusted brands such as Aurora®, MedReleaf®, and Whistler Medical Marijuana Corporation®, catering to medical markets across Canada, Europe, Australia, and New Zealand. Furthermore, with state-of-the-art GMP-certified manufacturing facilities located in Canada and Germany, Aurora continues to expand its influence within the global cannabis market.

The company trades under the symbol 'ACB' on both the NASDAQ and TSX exchanges, underpinning its stature in the industry as a significant player. Aurora is committed to transparency and adherence to regulatory frameworks, ensuring that all investors are informed about changes and decisions that may affect their investments.

In conclusion, Aurora Cannabis urges its shareholders to wait for further directions from the Board of Directors concerning Curaleaf's bid as the review unfolds. The regulatory landscape surrounding the cannabis industry remains ever-changing, making thorough evaluations essential for stakeholders.

For more detailed information, shareholders are encouraged to explore Aurora's official website and follow their updates on industry platforms.